ObjectiveTo explore the clinical effect of MORA biophysical therapeutic apparatus combined with inhaled budesonide formoterol aerosol on patients with allergic bronchial asthma. MethodsA total of 60 patients with moderate to severe chronic persistent bronchial asthma who were positive for allergens in our hospital from December 2016 to December 2018 were selected and randomly divided into observation group and control group, with 30 cases in each group. Patients in the control group were treated with budesonide formoterol, and patients in the observation group were treated with MORA biophysical therapy apparatus in combination with budesonide formoterol. The efficacy, lung function, asthma control test (ACT) score, daytime symptom score, nighttime symptom score and asthma quality of life questionnaire (AQLQ) score before and after treatment were compared between the two groups. ResultsThe total effective rate of the observation group (96.7%) was higher than that in the control group (80.0%), the difference was statistically significant (P＜0.05). After 3 months of treatment, the forced expiratory volume in 1 second (FEV1), percentage of forced expiratory volume in 1 second (FEV1%), and peak expiratory flow (PEF) were significantly increased in both groups, and observation group was significantly higher than those in the control group, the difference was statistically significant (P＜0.05). The ACT score and AQLA score of the two groups were significantly increased, and the daytime symptom score and nighttime symptom score were significantly decreased. The observation group had significantly higher ACT score and AQLA score as well as lower daytime symptom score and nighttime symptom score in comparison with the control group, the difference was statistically significant (P＜0.05). ConclusionThe MORA biophysical therapy apparatus combined with inhaled budesonide formoterol on allergic asthma patients has significant clinical effects, which can significantly improve lung function and life quality.

无